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Purpose/Objective: Curative (chemo-) radiation for head and neck 
cancer (HNC) may result in severe acute and late side effects, 
including tube feeding dependence. The purpose of this multicenter 
prospective cohort study was to develop a multivariate prediction 
model for tube feeding dependence 6 months (TUBEM6) after curative 
primary RT (radiotherapy), BioRT (radiotherapy + cetuximab) or CHRT 
(radiotherapy + chemotherapy) for head and neck cancer based on 
pre-treatment and treatment characteristics (including dose volume 
parameters) that can be used to select patients for radiotherapy 
treatment plan optimization.  
Materials and Methods: The study included 416 patients with HNC. In 
all patients, TUBEM6 was scored prospectively in a standardized follow-
up program. To design the prediction model, the penalized learning 
method LASSO was used, with TUBEM6 as the primary endpoint.  
Results: The incidence of TUBEM6 was 9.9% (41 out of 416 patients). 
Using the LASSO-parameter selection procedure, the multivariate 
model with the best model performance was selected, consisting of 
the following variables: male sex, advanced T-stage (T3-T4), 
moderate and severe weight loss at baseline, baseline CTCAE 
dysphagia-score, accelerated RT, CHRT, BioRT, the mean dose to the 
superior and inferior pharyngeal constrictor muscle (PCM), mean dose 
to the contralateral parotid gland and the mean dose to the 
cricopharyngeal muscle (CM) (see:Table). Model performance at 
internal validation in terms of area under the curve was 0.90 in 
double cross validation, while the prediction model scored excellent 
using other performance measures. Of the four dose-volume 
parameters, the mean dose to the PCM superior was most important.  
In the graph (see: Figure) an example of the predicted NTCP value for 
TUBEM6 as a function of the mean dose to the PCM superior is shown 
for a female patient with a T3-T4 tumor, with severe weight loss and 
dysphagia prior to the start of chemoradiotherapy.  
 
 
  
Conclusions: We developed a multivariate NTCP model for TUBEM6 
after definitive (chemo) radiation, which can be used to predict 
TUBEM6. The four dosimetric variables in this prediction model can be 
used to optimize RT treatment planning aiming at prevention of tube 
feeding dependence.  
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Purpose/Objective: To evaluate the prognostic significance of 
quantitative advanced imaging features derived from diagnostic CT 
images in HNSCC patients.We hypothesized that non-invasive imaging 
features of the tumor such as heterogeneity and shape extracted from 
already available CT images are prognostic for survival. 
Materials and Methods: Retrospective analysis of 150 patients with 
SCC of the head and neck (49 larynx and 101 oropharynx tumors) 
treated with radiotherapy alone or chemo-radiation with curative 
intent. All patients underwent a CT scan for treatment planning. The 
primary tumor was delineated by an experienced radiation oncologist 
on CT images. A set of 80 imaging features were automatically 
extracted from the tumor region on the CT scan, including 15 first 
order statistics, 33 textural features derived from gray level co-
occurrence and rung-length matrices, 24 textural wavelet features 
and 7 tumor shape metrics (Fig 1). For comparisons of CT features the 
Mann-Whitney U test was used to determine differences on overall 
survival. For TNM the Chi-square test was used. The Relieff algorithm 
was used to rank the CT features according to their importance 
attributes. Univariate and multivariate Cox proportional hazards 
models were used to compare the risk of death among patients. The 
performance of the model was evaluated with a 5-fold cross validated 
c-index.  
 
 Figure 1. Patients underwent a CT scan for treatment planning. The 
primary tumor was delineated by a radiation oncologist on the CT 
scan. The extracted CT features were evaluated for their association 
with overall survival.  
Results: The median survival was 64 months (95% CI, 58-71 months) 
and the median follow up was 35 months(range: 0.7-94), with a death 
event rate of 34 %. The results of the univariate analysis are shown in 
Table 1 for the top ranked features and for examples of features that 
were not significant. 39 CT features had significant differences among 
the overall survival groups. The combination of the top four 
parameters in the univariate analysis in a multivariate model rendered 
c-index of 0.77(CI, 0.69 – 0.83). This c-index was better than the 
observed for TNM. 
 
 
Conclusions: This preliminary analysis shows that advanced textural 
and shape features are prognostic for survival in HNSCC patients. The 
multivariate model based on CT features and even individual CT 
features had a better discriminatory power than TNM for survival. 
Further analysis involves the association of CT features with loco-
regional tumor control and a sub-analysis per tumor anatomical 
location. External validation of these results will follow.  
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Purpose/Objective: Treatment of head and neck squamous cell 
carcinomas (HNSCC) with radiotherapy and the epidermal growth 
factor (EGFR) inhibitor cetuximab has shown promising results, but is 
only effective in a fraction of HNSCC patients. Patient selection is 
based on EGFR expression as determined immunohistochemically, but 
this does not correlate with treatment response. The aim of this study 
was to develop and characterize the 111In-cetuximab-F(ab’)2 tracer for 
imaging EGFR expression and to determine if tracer uptake correlates 
with response to EGFR-inhibitor treatment in HNSCC xenografts. 
Materials and Methods: The optimal protein dose and imaging time-
point was determined in athymic mice with s.c. FaDu xenografts. 
Subsequently, mice with HNSCC xenografts SCCNij202, 167, 185 and 
153 were imaged with 111In-cetuximab-F(ab’)2. 
Results: The highest uptake of 111In-cetuximab-F(ab’)2 in FaDu tuors 
was obtained at doses of 5 µg/mouse (13.50 ± 5.17 %ID/g). Due to the 
rapid blood clearance, tumor-to-blood ratios were high for 111In-
cetuximab-F(ab’)2 (31.4 ± 3.8 at 24 h p.i.). MicroSPECT images showed 
preferential uptake in HNSCC xenografts; 3.1 ± 0.2 (SCCNij202), 2.8 ± 
0.4 (SCCNij153), 2.0 ± 0.8 (SCCNij185), 2.0 ± 0.4 (SCCNij167) %ID/g. 
Overall tumor uptake of 111In-cetuximab-F(ab’)2 correlated well with 
immuno-histochemical EGFR fractions (r=0.61, p<0.01). Growth delay 
experiments showed that SCCNij202 responded to cetuximab 
treatment whereas SCCNij167, SCCNij185 and SCCNij153 were non-
responders. 
Conclusions: 111In-cetuximab-F(ab’)2 showed a clear heterogeneous 
distribution throughout the tumor. Tumor uptake correlated with 
treatment response in three out of four HNSCC xenografts.  
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Purpose/Objective: Among head and neck cancer survivors many 
experience diminished quality of life owing to side effects following 
treatment; one of the predominant side effects is dysphagia, 
regardless of the treatment modality involved. The aim of this study 
was to investigate frequency, intensity and dose-volume 
characteristics for late dysphagia in head and neck cancer patients 
treated with curative IMRT.  
Table 1. Univariate analysis of CT imaging features and for their
association with survival 
 5 year survival 
= Yes  
(n = 99) 
5 year survival 
= No  
(n = 51) 
p C-
index 
Wavelet_Texture_1 3.0306 ±1.2007 5.4806 ± 7.6906 0.000 0.78 
Shape_3 56.22 ± 104.45 105.44 ± 78.48 0.000 0.77 
Volume 28.27 ± 104.01 55.87 ± 64.63 0.000 0.76 
Shape_5 0.65 ± 0.69 1.15 ± 0.72 0.000 0.76 
Shape_4 4.54 ±2.67 2.71 ± 1.03 0.000 0.74 
TNM 
1 
2 
3 
4 
33 
25 
13 
28 
8 
9 
12 
22 
0.028 0.66 
Texture_1st_6 1054.41 ± 26.80 1064.79 ± 22.53 0.131 0.58 
Texture_1st_4 1068.22 ± 17.13 1070.21 ± 14.19 0.982 0.44 
